145,289 Shares in Tempus AI, Inc. (NASDAQ:TEM) Acquired by Sculptor Capital LP

Sculptor Capital LP purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 145,289 shares of the company’s stock, valued at approximately $5,085,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Sandia Investment Management LP acquired a new stake in shares of Tempus AI during the second quarter worth $136,000. Northwestern University bought a new position in Tempus AI in the second quarter valued at about $491,000. Squarepoint Ops LLC bought a new position in Tempus AI in the second quarter valued at about $633,000. WINTON GROUP Ltd bought a new position in Tempus AI in the second quarter valued at about $634,000. Finally, The Manufacturers Life Insurance Company bought a new position in Tempus AI in the second quarter valued at about $946,000.

Tempus AI Stock Up 5.5 %

Shares of Tempus AI stock opened at $51.87 on Friday. The stock’s fifty day moving average is $49.38. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $77.00.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($6.77) earnings per share for the quarter, missing the consensus estimate of ($4.41) by ($2.36). The firm had revenue of $165.97 million during the quarter, compared to the consensus estimate of $159.10 million. On average, equities analysts anticipate that Tempus AI, Inc. will post -6.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on TEM. William Blair assumed coverage on Tempus AI in a research report on Tuesday, July 9th. They issued an “outperform” rating on the stock. Morgan Stanley assumed coverage on Tempus AI in a report on Tuesday, July 9th. They set an “overweight” rating and a $44.00 price target on the stock. Bank of America started coverage on Tempus AI in a report on Tuesday, July 9th. They set a “buy” rating and a $41.00 price target on the stock. Longbow Research started coverage on Tempus AI in a research note on Tuesday, July 9th. They issued a “buy” rating and a $48.00 price objective on the stock. Finally, Piper Sandler started coverage on Tempus AI in a research note on Monday, August 12th. They issued a “neutral” rating and a $40.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and a consensus price target of $45.56.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.